RAPT Therapeutics, Inc. (NASDAQ:RAPT) Short Interest Update

RAPT Therapeutics, Inc. (NASDAQ:RAPT) saw a significant decrease in short interest during the month of January. As of January 15th, there was short interest totalling 2,640,000 shares, a decrease of 25.8% from the December 31st total of 3,560,000 shares. Based on an average trading volume of 3,320,000 shares, the days-to-cover ratio is presently 0.8 days.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. JPMorgan Chase & Co. downgraded RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Monday, November 11th. Wells Fargo & Company cut their price objective on shares of RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a research report on Tuesday, November 12th. Piper Sandler downgraded RAPT Therapeutics from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $8.00 to $2.00 in a research report on Monday, November 11th. HC Wainwright upgraded RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 price target for the company in a research report on Thursday, December 26th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $2.00 price objective (down from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, RAPT Therapeutics has a consensus rating of “Hold” and an average target price of $9.56.

Institutional Investors Weigh In On RAPT Therapeutics

Several large investors have recently bought and sold shares of the business. Readystate Asset Management LP purchased a new position in shares of RAPT Therapeutics in the 3rd quarter worth $36,000. JPMorgan Chase & Co. increased its stake in RAPT Therapeutics by 298.2% during the third quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock worth $34,000 after acquiring an additional 25,130 shares during the last quarter. Barclays PLC lifted its stake in shares of RAPT Therapeutics by 277.2% in the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock valued at $79,000 after purchasing an additional 29,195 shares during the last quarter. SG Americas Securities LLC boosted its holdings in shares of RAPT Therapeutics by 401.9% in the 4th quarter. SG Americas Securities LLC now owns 53,244 shares of the company’s stock worth $84,000 after purchasing an additional 42,636 shares during the period. Finally, Exchange Traded Concepts LLC increased its position in shares of RAPT Therapeutics by 244.7% during the 3rd quarter. Exchange Traded Concepts LLC now owns 89,076 shares of the company’s stock valued at $179,000 after purchasing an additional 63,235 shares during the last quarter. Institutional investors own 99.09% of the company’s stock.

RAPT Therapeutics Stock Down 2.6 %

RAPT opened at $1.14 on Friday. RAPT Therapeutics has a fifty-two week low of $0.79 and a fifty-two week high of $27.35. The company has a fifty day moving average of $1.26 and a 200 day moving average of $1.88.

RAPT Therapeutics (NASDAQ:RAPT) last posted its earnings results on Tuesday, November 12th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.09. Sell-side analysts predict that RAPT Therapeutics will post -2.43 earnings per share for the current year.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.